Skip to main content
SpringerLink
Log in

Surgery and Imatinib in the Management of GIST: Emerging Approaches to Adjuvant and Neoadjuvant Therapy

  • Educational Review
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

Gastrointestinal stromal tumor (GIST) is a neoplasm of the gastrointestinal tract, mesentery, or omentum that expresses the protein-tyrosine kinase KIT (CD117) and is the most common mesenchymal tumor arising at these sites. Surgical resection is the first-line intervention for operable GISTs, particularly localized primary tumors, and it was historically the only effective treatment. However, more than half of all GIST patients present with locally advanced, recurrent, or metastatic disease. The 5-year survival rate ranges from 50% to 65% after complete resection of a localized primary GIST and decreases to approximately 35% for patients with advanced disease who undergo complete surgical resection. A total of 40% to 90% of all GIST surgical patients subsequently have postoperative recurrence or metastasis. Imatinib is a potent, specific inhibitor of KIT that has demonstrated significant activity and tolerability in the treatment of malignant unresectable or metastatic GIST, inducing tumor shrinkage of 50% or more or stabilizing disease in most patients. A key strategy for prolonging the survival of patients with GIST is to improve the outcome of surgery. It is possible that the adjuvant and neoadjuvant use of imatinib (e.g., rendering initially inoperable tumors resectable) in the overall management approach to advanced GIST may contribute to surgeons’ success in attaining this objective.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

REFERENCES

  1. Walsh NM, Bodurtha A. Auerbach’s myenteric plexus. A possible site of origin for gastrointestinal stromal tumors in von Recklinghausen’s neurofibromatosis. Arch Pathol Lab Med 1990;114:522–5.

    PubMed  CAS  Google Scholar 

  2. Kindblom LG, Remotti HE, Aldenberg F, Meis-Kindblom JM. Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. Am J Pathol 1998;152:1259–69.

    CAS  PubMed  Google Scholar 

  3. Sarlomo-Rikala M, Kovatich AJ, Barusevicius A, Miettinen M. CD117: a sensitive marker for gastrointestinal stromal tumors that is more specific than CD34. Mod Pathol 1998;11:728–34.

    CAS  PubMed  Google Scholar 

  4. Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998;279:577–80.

    Article  CAS  PubMed  Google Scholar 

  5. Mazur MT, Clark HB. Gastric stromal tumors. Reappraisal of histogenesis. Am J Surg Pathol 1983;7:507–19.

    CAS  PubMed  Google Scholar 

  6. Lux ML, Rubin BP, Biase TL, et al. KIT extracellular and kinase domain mutations in gastrointestinal stromal tumors. Am J Pathol 2000;156:791–5.

    CAS  PubMed  Google Scholar 

  7. Rubin BP, Singer S, Tsao C, et al. KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Res 2001;61:8118–21.

    CAS  PubMed  Google Scholar 

  8. Miettinen M, Lasota J. Gastrointestinal stromal tumors—definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis. Virchows Arch 2001;438:1–12.

    Article  CAS  PubMed  Google Scholar 

  9. Fletcher CDM, Berman JJ, Corless C, et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol 2002;33:459–65.

    Article  PubMed  Google Scholar 

  10. Buchdunger E, Zimmermann J, Mett H, et al. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res 1996;56:100–4.

    CAS  PubMed  Google Scholar 

  11. Buchdunger E, Cioffi CL, Law N, et al. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-Kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 2000;295:139–45.

    CAS  PubMed  Google Scholar 

  12. Heinrich MC, Griffith DJ, Druker BJ, Wait CL, Ott KA, Zigler AJ. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood 2000;96:925–32.

    CAS  PubMed  Google Scholar 

  13. van Oosterom AT, Judson I, Verweij J, et al. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet 2001;358:1421–3.

    Article  PubMed  CAS  Google Scholar 

  14. van Oosterom AT, Judson IR, Verweij J, et al. Update of phase I study of imatinib (STI571) in advanced soft tissue sarcomas and gastrointestinal stromal tumors: a report of the EOERTIC Soft Tissue and Bone Sarcoma Group. Eur J Cancer. 38;(Suppl 5), 2002: S83–7

    Article  PubMed  Google Scholar 

  15. Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002;347:472–80.

    Article  CAS  PubMed  Google Scholar 

  16. DeMatteo RP, Lewis JJ, Leung D, Mudan SS, Woodruff JM, Brennan MF. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg 2000;231:51–8.

    Article  CAS  PubMed  Google Scholar 

  17. Roberts PJ, Eisenberg B. Clinical presentation of gastrointestinal stromal tumors and treatment of operable disease. Eur J Cancer. 38;(Suppl 5). 2002: S37–8.

    Article  CAS  PubMed  Google Scholar 

  18. Sturgeon C, Chejfec G, Espat NJ. Gastrointestinal stromal tumors: a spectrum of disease. Surg Oncol 2003;12:21–6.

    PubMed  Google Scholar 

  19. Lewis JJ, Brennan MF. Soft tissue sarcomas. Curr Probl Surg 1996;33:817–72.

    PubMed  CAS  Google Scholar 

  20. Crosby JA, Catton CN, Davis A, et al. Malignant gastrointestinal stromal tumors of the small intestine: a review of 50 cases from a prospective database. Ann Surg Oncol 2001;8:50–9.

    PubMed  CAS  Google Scholar 

  21. Nishida T, Hirota SI. Biological and clinical review of stromal tumors in the gastrointestinal tract. Histol Histopathol 2000;15:1293–301.

    PubMed  CAS  Google Scholar 

  22. Miettinen M, Sobin LH, Sarlomo-Rikala M. Immunohistochemical spectrum of GISTs at different sites and their differential diagnosis with a reference to CD117 (KIT). Mod Pathol 2000;13:1134–42.

    Article  CAS  PubMed  Google Scholar 

  23. Kindblom L-G, Meis-Kindblom J, Bümming P, et al. Incidence, prevalence, phenotype and biologic spectrum of gastrointestinal stromal cell tumors (GIST)—a population-based study of 600 cases. Ann Oncol. 13;(Suppl 5), 2002: 157

    Article  CAS  PubMed  Google Scholar 

  24. Blanke CD, Eisenberg BL, Heinrich MC. Gastrointestinal stromal tumors. Curr Treat Options Oncol 2001;2:485–91.

    PubMed  CAS  Google Scholar 

  25. Miettinen M, Majidi M, Lasota J. Pathology and diagnostic criteria of gastrointestinal stromal tumors (GISTs): a review. Eur J Cancer. 38;(Suppl 5), 2002: S39–51.

    Article  PubMed  Google Scholar 

  26. Bauer S, Corless CL, Heinrich MC. Response to imatinib mesylate of a gastrointestinal stromal tumor with very low expression of KIT. Cancer Chemother Pharmacol 2003;51:261–5.

    PubMed  Google Scholar 

  27. Sabah M, Leader M, Kay E. The problem with KIT: clinical implications and practical difficulties with CD117 immunostaining. Appl Immunohistochem Mol Morphol 2003;11:56–61.

    Article  CAS  PubMed  Google Scholar 

  28. Pidhorecky I, Cheney RT, Kraybill WG, Gibbs JF. Gastrointestinal stromal tumors: current diagnosis, biologic behavior, and management. Ann Surg Oncol 2000;7:705–12.

    CAS  PubMed  Google Scholar 

  29. DeMatteo RP, Maki RG, Antonescu C, Brennan MF. Targeted molecular therapy for cancer: the application of STI571 to gastrointestinal stromal tumor. Curr Probl Surg 2003;40:144–93.

    Article  PubMed  Google Scholar 

  30. Lehnert T. Gastrointestinal sarcoma (GIST)—a review of surgical management. Ann Chir Gynaecol 1998;87:297–305.

    PubMed  CAS  Google Scholar 

  31. Miettinen M, Furlong M, Sarlomo-Rikala M, Burke A, Sobin LH, Lasota J. Gastrointestinal stromal tumors, intramural leiomyomas, and leiomyosarcomas in the rectum and anus. A clinicopathologic, immunohistochemical, and molecular genetic study of 144 cases. Am J Surg Pathol 2001;25:1121–33.

    Article  CAS  PubMed  Google Scholar 

  32. Hasegawa T, Matsuno Y, Shimoda T, Hirohashi S. Gastrointestinal stromal tumor: consistent CD117 immunostaining for diagnosis, and prognostic classification based on tumor size and MIB-1 grade. Hum Pathol 2002;33:669–76.

    Article  PubMed  Google Scholar 

  33. Judson I. Gastrointestinal stromal tumours (GIST): biology and treatment. Ann Oncol. 13;(Suppl 4), 2002: 287–9.

    PubMed  Google Scholar 

  34. Emory TS, O’Leary TJ. Prognosis and surveillance of gastrointestinal stromal/smooth muscle tumors. Ann Chir Gynaecol 1998;87:306–10.

    CAS  PubMed  Google Scholar 

  35. Miettinen M, El-Rifai W, Sobin LH, Lasota J. Evaluation of malignancy and prognosis of gastrointestinal stromal tumors: a review. Hum Pathol 2002;33:478–83.

    Article  PubMed  CAS  Google Scholar 

  36. Miettinen M, Sarlomo-Rikala M, Sobin LH, Lasota J. Esophageal stromal tumors: a clinicopathologic, immunohistochemical, and molecular genetic study of 17 cases and comparison with esophageal leiomyomas and leiomyosarcomas. Am J Surg Pathol 2000;24:211–22.

    PubMed  CAS  Google Scholar 

  37. Pierie JP, Choudry U, Muzikansky A, Yeap BY, Souba WW, Ott MJ. The effect of surgery and grade on outcome of gastrointestinal stromal tumors. Arch Surg 2001;136:383–9.

    Article  CAS  PubMed  Google Scholar 

  38. Burkill GJC, Badran M, Al-Muderis O, et al. Malignant gastrointestinal stromal tumor: distribution, imaging features, and pattern of metastatic spread. Radiology 2003;226:527–32.

    PubMed  Google Scholar 

  39. Ludwig K, Wilhelm L, Scharlau U, Amtsberg G, Bernhardt J. Laparoscopic-endoscopic rendezvous resection of gastric tumors. Surg Endosc 2001;16:1561–5.

    Google Scholar 

  40. Tagaya N, Mikami H, Kogure H, Kubota K, Hosoya Y, Nagai H. Laparoscopic intragastric stapled resection of gastric submucosal tumors located near the esophagogastric junction. Surg Endosc 2002;16:177–9.

    Article  CAS  PubMed  Google Scholar 

  41. Rothlin M, Schob O. Laparoscopic wedge resection for benign gastric tumors. Surg Endosc 2001;15:893–5.

    Article  CAS  PubMed  Google Scholar 

  42. Mainprize KS, Dehn TC. Laparoscopic management of pseudoachalasia, esophageal diverticulum, and benign esophageal stromal tumor. Dis Esophagus 2001;14:73–5.

    PubMed  CAS  Google Scholar 

  43. Shirai H, Takeuchi T, Naka T, et al. Gastrointestinal stromal tumor of the stomach: report of a case. Surg Today 2001;31:346–9.

    PubMed  CAS  Google Scholar 

  44. Matsui H, Uyama I, Fujita J, Komori Y, Sugioka A, Hasumi A. Gastrointestinal stromal tumor of the stomach successfully treated by laparoscopic proximal gastrectomy with jejunal interposition. Surg Laparosc Endosc Percutan Tech 2000;10:239–42.

    PubMed  CAS  Google Scholar 

  45. Otani Y, Ohgami M, Igarashi N, et al. Laparoscopic wedge resection of gastric submucosal tumors. Surg Laparosc Endosc Percutan Tech 2000;10:19–23.

    PubMed  CAS  Google Scholar 

  46. Cheng HL, Lee WJ, Lai IR, Yuan RH, Yu SC. Laparoscopic wedge resection of benign gastric tumor. Hepatogastroenterology 1999;46:2100–4.

    CAS  PubMed  Google Scholar 

  47. Cueto J, Vazquez-Frias JA, Castaneda-Leeder P, Baquera-Heredia J, Weber-Sanchez A. Laparoscopic-assisted resection of a bleeding gastrointestinal stromal tumor. JSLS 1999;3:225–8.

    PubMed  CAS  Google Scholar 

  48. Wolfsohn DM, Savides TJ, Easter DW, Lyche KD. Laparoscopy-assisted endoscopic removal of a stromal-cell tumor of the stomach. Endoscopy 1997;29:679–82.

    Article  PubMed  CAS  Google Scholar 

  49. Heinrich MC, Blanke CD, Druker BJ, Corless CL. Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies. J Clin Oncol 2002;20:1692–703.

    Article  CAS  PubMed  Google Scholar 

  50. Joensuu H, Fletcher C, Dimitrijevic S, Silberman S, Roberts P, Demetri G. Management of malignant gastrointestinal stromal tumors. Lancet Oncol 2002;3:655–64.

    Article  CAS  PubMed  Google Scholar 

  51. Ng EH, Pollock RE, Munsell MF, Atkinson EN, Romsdahl MM. Prognostic factors influencing survival in gastrointestinal leiomyosarcomas. Implications for surgical management and staging. Ann Surg 1992;215:68–77.

    Article  CAS  PubMed  Google Scholar 

  52. Langer C, Gunawan B, Schuler P, Huber W, Fuzesi L, Becker H. Prognostic factors influencing surgical management and outcome of gastrointestinal stromal tumours. Br J Surg 2003;90:332–9.

    PubMed  CAS  Google Scholar 

  53. Piso P, Schlitt HJ, Klempnauer J. Stromal sarcoma of the stomach: therapeutic considerations. Eur J Surg 2000;166:954–8.

    PubMed  CAS  Google Scholar 

  54. Mudan SS, Conlon KC, Woodruff JM, Lewis JJ, Brennan MF. Salvage surgery for patients with recurrent gastrointestinal sarcoma: prognostic factors to guide patient selection. Cancer 2000;88:66–74.

    Article  CAS  PubMed  Google Scholar 

  55. De Pas T, Casali PG, Toma S, et al. Gastrointestinal stromal tumors: should they be treated with the same systemic chemotherapy as other soft tissue sarcomas?. Oncology 2003;64:186–8.

    PubMed  Google Scholar 

  56. DeMatteo RP, Shah A, Fong Y, Jarnagin WR, Blumgart LH, Brennan MF. Results of hepatic resection for sarcoma metastatic to liver. Ann Surg 2001;234:540–7.

    Article  CAS  PubMed  Google Scholar 

  57. Tervahartiala P, Halavaara J. Radiology of GIST. Ann Chir Gynaecol 1998;87:291–2.

    PubMed  CAS  Google Scholar 

  58. Eilber FC, Rosen G, Forscher C, Nelson SD, Dorey F, Eilber FR. Recurrent gastrointestinal stromal sarcomas. Surg Oncol 2000;9:71–5.

    PubMed  CAS  Google Scholar 

  59. Patel SR, Benjamin RS. Management of peritoneal and hepatic metastases from gastrointestinal stromal tumors. Surg Oncol 2000;9:67–70.

    PubMed  CAS  Google Scholar 

  60. Bhattacharya R, Rao S, Kowdley KV. Liver involvement in patients with solid tumors of nonhepatic origin. Clin Liver Dis 2002;6:1033–43.

    PubMed  Google Scholar 

  61. Bloomston M, Binitie O, Fraiji E, et al. Transcatheter arterial chemoembolization with or without radiofrequency ablation in the management of patients with advanced hepatic malignancy. Am Surg 2002;68:827–31.

    PubMed  Google Scholar 

  62. Tarazov PG. Transcatheter therapy of gastric cancer metastatic to the liver: preliminary results. J Gastroenterol 2000;35:907–11.

    PubMed  CAS  Google Scholar 

  63. Heinrich MC, Rubin BP, Longley BJ, Fletcher JA. Biology and genetic aspects of gastrointestinal stromal tumors: KIT activation and cytogenetic alterations. Hum Pathol 2002;33:484–95.

    Article  CAS  PubMed  Google Scholar 

  64. Heinrich MC, Corless CL, Duensing A, et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science 2003;299:708–10.

    Article  CAS  PubMed  Google Scholar 

  65. Nishida T, Kumano S, Sugiura T, et al. Multidetector CT of high-risk patients with occult gastrointestinal stromal tumors. AJR Am J Roentgenol 2003;180:185–9.

    PubMed  Google Scholar 

  66. Joensuu H, Roberts PJ, Sarlomo-Rikala M, et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 2001;344:1052–6.

    Article  CAS  PubMed  Google Scholar 

  67. Van den Abbeele AD, Badawi RD. Use of positron emission tomography in oncology and its potential role to assess response to imatinib mesylate therapy in gastrointestinal stromal tumors (GISTs). Eur J Cancer. 38;(Suppl 5), 2002: S60–5

    PubMed  Google Scholar 

  68. Högenauer C, Langner C, Lipp RW, Höfler G, Krejs GJ, Hinterleitner TA. Complete remission of a metastatic gastrointestinal stromal tumour with the tyrosine kinase inhibitor imatinib (STI 571): effect of low dosage in an advanced tumour with exon 11 mutation. Eur J Gastroenterol Hepatol 2003;15:323–7.

    PubMed  Google Scholar 

  69. Verweij J, Casali P, Zalcberg J, et al. Early efficacy comparison of two doses of imatinib for the treatment of advanced gastrointestinal stromal tumors (GIST): interim results of a randomized phase III trial from the EORTC-STBSG, ISG and AGITG. Proc Am Soc Clin Oncol 2003;22:814.

    Google Scholar 

  70. Benjamin RS, Rankin C, Fletcher C, et al. Phase III dose-randomized study of imatinib mesylate (STI571) for GIST: Intergroup S0033 early results. Proc Am Soc Clin Oncol 2003;22:814.

    Google Scholar 

  71. Eisenberg BL, von Mehren M. Pharmacotherapy of gastrointestinal stromal tumours. Expert Opin Pharmacother 2003;4:869–74.

    PubMed  CAS  Google Scholar 

  72. Hohenberger P, Bauer S, Schneider U, et al. Tumor resection following imatinib pretreatment in GI stromal tumors. Proc Am Soc Clin Oncol 2003;22:818.

    Google Scholar 

  73. Buemming P, Meis-Kindblom JM, Kindblom L-G, et al. Is there an indication for adjuvant treatment with imatinib mesylate in patients with aggressive gastrointestinal stromal tumors (GISTs)?. Proc Am Soc Clin Oncol 2003;22:818.

    Google Scholar 

  74. Corless CL, McGreevey L, Haley A, Town A, Heinrich MC. KIT mutations are common in incidental gastrointestinal stromal tumors one centimeter or less in size. Am J Pathol 2002;160:1567–72.

    PubMed  CAS  Google Scholar 

  75. Ernst SI, Hubbs AE, Przygodzki RM, Emory TS, Sobin LH, O’Leary TJ. KIT mutation portends poor prognosis in gastrointestinal stromal/smooth muscle tumors. Lab Invest 1998;78:1633–6.

    PubMed  CAS  Google Scholar 

  76. Lasota J, Jasinski M, Sarlomo-Rikala M, Miettinen M. Mutations in exon 11 of c-Kit occur preferentially in malignant versus benign gastrointestinal stromal tumors and do not occur in leiomyomas or leiomyosarcomas. Am J Pathol 1999;154:53–60.

    CAS  PubMed  Google Scholar 

  77. Taniguchi M, Nishida T, Hirota S, et al. Effect of c-kit mutation on prognosis of gastrointestinal stromal tumors. Cancer Res 1999;59:4297–300.

    PubMed  CAS  Google Scholar 

  78. Sakurai S, Fukasawa T, Chong JM, Tanaka A, Fukayama M. C-kit gene abnormalities in gastrointestinal stromal tumors (tumors of interstitial cells of Cajal). Jpn J Cancer Res 1999;90:1321–8.

    PubMed  CAS  Google Scholar 

  79. Andersson J, Sjögren H, Meis-Kindblom JM, Stenman G, Åman P, Kindblom L-G. The complexity of KIT gene mutations and chromosome rearrangements and their clinical correlation in gastrointestinal stromal (pacemaker cell) tumors. Am J Pathol 2002;160:15–22.

    PubMed  CAS  Google Scholar 

  80. Wardelmann E, Neidt I, Bierhoff E, et al. c-kit Mutations in gastrointestinal stromal tumors occur preferentially in the spindle rather than in the epithelioid cell variant. Mod Pathol 2002;15:125–36.

    Article  PubMed  Google Scholar 

  81. Singer S, Rubin BP, Lux ML, et al. Prognostic value of KIT mutation type, mitotic activity, and histologic subtype in gastrointestinal stromal tumors. J Clin Oncol 2002;20:3898–905.

    PubMed  CAS  Google Scholar 

  82. Lasota J, Wozniak A, Sarlomo-Rikala M, et al. Mutations in exons 9 and 13 of KIT gene are rare events in gastrointestinal stromal tumors. A study of 200 cases. Am J Pathol 2000;157:1091–5.

    CAS  PubMed  Google Scholar 

  83. Hirota S, Nishida T, Isozaki K, et al. Gain-of-function mutation at the extracellular domain of KIT in gastrointestinal stromal tumors. J Pathol 2001;193:505–10.

    PubMed  CAS  Google Scholar 

  84. Sakurai S, Oguni S, Hironaka M, Fukayama M, Morinaga S, Saito K. Mutations in c-kit gene exons 9 and 13 in gastrointestinal stromal tumors among Japanese. Jpn J Cancer Res 2001;92:494–8.

    PubMed  CAS  Google Scholar 

  85. Heinrich MC, Corless CL, Blanke C, et al. KIT mutational status predicts clinical response to STI571 in patients with metastatic gastrointestinal stromal tumors (GISTs) (abstract). Proc Am Soc Clin Oncol 2002;21:2a.

    Google Scholar 

  86. de Silva MVC, Reid R. Gastrointestinal stromal tumors (GIST): c-kit mutations, CD117 expression, differential diagnosis and targeted cancer therapy with imatinib. Pathol Oncol Res 2003;9:13–9.

    Article  PubMed  Google Scholar 

  87. Miettinen M, Sarlomo-Rikala M, Lasota J. Gastrointestinal stromal tumors: recent advances in understanding of their biology. Hum Pathol 1999;30:1213–20.

    Article  CAS  PubMed  Google Scholar 

  88. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000;92:205–16.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Norris Cotton Cancer Center, Lebanon, New Hampshire

    Burton L. Eisenberg MD

  2. Institute of Cancer Research, Surrey, United Kingdom

    Ian Judson MD

  3. Section of Surgical Oncology, Norris Cotton Cancer Center, Rubin Building, 8th Floor, Dartmouth Hitchcock Medical Center, One Medical Center Drive , Lebanon, NH, 03756

    Burton L. Eisenberg MD

Authors
  1. Burton L. Eisenberg MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ian Judson MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Burton L. Eisenberg MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Eisenberg, B.L., Judson, I. Surgery and Imatinib in the Management of GIST: Emerging Approaches to Adjuvant and Neoadjuvant Therapy. Ann Surg Oncol 11, 465–475 (2004). https://doi.org/10.1245/ASO.2004.09.011

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1245/ASO.2004.09.011

Key Words

Search

Navigation